---
title: Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment
euct_id: 2025-520754-11-00
phase: Phase 3
status: Recruiting
sponsor: Bial R&D Investments S.A.
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-520754-11-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-520754-11-00"
ctis_last_updated: "2025-12-11T02:41:49.273649415"
source: EU Clinical Trials Information System (CTIS)
---
# Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

**EU CT Number:** [2025-520754-11-00](https://euclinicaltrials.eu/ctis-public/view/2025-520754-11-00)

## Key Facts

- **Phase:** Phase 3
- **Status:** Recruiting
- **Sponsor:** Bial R&D Investments S.A.
- **Start Date:** 2025-08-26
- **Completion Date:** 2026-07-29
- **Conditions:** Parkinson's disease

## Member States

Trial is authorized in 1 member state: Hungary.

## Sites (1)

- CRU Hungary Kft., Kistarcsa, Hungary

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-520754-11-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-520754-11-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-520754-11-00*